Natera’s Signatera wins Japan PMDA approval as companion diagnostic in muscle-invasive bladder cancer

Bitget2026/09/22 12:04

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Natera won PMDA clearance in Japan for Signatera as a companion diagnostic in muscle-invasive bladder cancer.
Authorization supports MRD-guided adjuvant use of Roche’s Tecentriq (atezolizumab) in eligible post-surgery patients.
Commercial launch targeted for 1H 2027, pending final reimbursement and pricing decisions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Natera Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202609220800BIZWIRE_USPR_____20260922_BW775835) on September 22, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Natera’s Signatera wins Japan PMDA approval as companion diagnostic in muscle-invasive bladder cancer

You may also like

Crypto prices